Publicaciones en las que colabora con Josép María Ribera Santasusana (10)

2011

  1. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

    Blood, Vol. 118, Núm. 17, pp. 4547-4553

2010

  1. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome

    Blood, Vol. 115, Núm. 25, pp. 5137-5146

2008

  1. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy

    Journal of Clinical Oncology, Vol. 26, Núm. 16, pp. 2737-2744

2005

  1. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

    Blood, Vol. 106, Núm. 12, pp. 3755-3759

2002

  1. Erratum: «Recomendaciones GESIDA/PETHEMA sobre el diagnóstico y tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana» (Medicina Clinica (2002) vol. 118 (225-36))

    Medicina Clinica

  2. GESIDA/PETHEMA guidelines for the diagnosis and treatment of lymphomas in HIV-infected patients

    Medicina Clinica

2001

  1. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracycline-based protocol. A report from the spanish group PETHEMA

    Haematologica, Vol. 86, Núm. 8, pp. 807-813

  2. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: A study of the PETHEMA group

    British Journal of Haematology, Vol. 114, Núm. 1, pp. 99-103

2000

  1. Definition of relapse risk and role of nonanthracycline drags for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups

    Blood, Vol. 96, Núm. 4, pp. 1247-1253

1999

  1. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia

    Blood, Vol. 94, Núm. 9, pp. 3015-3021